Patents by Inventor Owen N. Witte

Owen N. Witte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for detecting the presence of a PSCA protein using PSCA antibodies
    Patent number: 6261789
    Abstract: The invention provides methods for detecting the presence of a PSCA protein comprising contacting the sample with PSCA antibodies designated 1G8 (ATCC No. HB-12612), 2A2 (ATCC No. HB-12613), 2H9 (ATCC No. HB-12614), 3C5 (ATCC No. HB-12616), 3E6 (ATCC No. HB12618), 3G3 (ATCC No. HB-12615), or 4A10 (ATCC No. HB-12617).
    Type: Grant
    Filed: February 17, 1999
    Date of Patent: July 17, 2001
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte
  • PSCA antibodies and hybridomas producing them
    Patent number: 6258939
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: July 10, 2001
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte
  • Transcriptionally regualted G protein-coupled receptor
    Patent number: 6214562
    Abstract: A G protein-coupled receptor (GPCR), called G2A, whose expression is regulated and functions at the G2/M checkpoint to ensure properly controlled duplication of hematopoietic cells. The receptor is found predominantly in hematopoietic cells and tissues and functions as a tumor suppressor gene and induces cell cycle arrest. This receptor may play an important role in regulating the proliferation and differentiation of hematopoietic cells. Regulation of receptor activity has several therapeutic applications.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: April 10, 2001
    Assignee: The Regents of the University of California
    Inventors: Zhigang Weng, Owen N. Witte
  • Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells
    Patent number: 6207412
    Abstract: A G protein-coupled receptor (GPCR) which is activated by oncogenes. The receptor is found predominantly in hematopoietic cells and tissues and functions as a tumor suppressor gene and induces cell cycle arrest. This receptor may play an important role in regulating the proliferation and differentiation of hematopoietic cells. Regulation of receptor activity has several therapeutic applications.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: March 27, 2001
    Assignee: The Regents of the University of California
    Inventors: Zhigang Weng, Owen N. Witte
  • Mice models of human prostate cancer progression
    Patent number: 6107540
    Abstract: The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: August 22, 2000
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyer, Karen A. Klein, Owen N. Witte, Robert E. Reiter
  • E25a protein, methods for production and use thereof
    Patent number: 6093800
    Abstract: The invention provides a human E25a protein which is upregulated in cancerous cells, including those of hormone refractory prostate cancer, colon cancer, breast cancer or other cancers of epithelial origin. The invention also provides nucleic acid molecules encoding E25a protein, nucleic acid probes which hybridize with nucleic acid molecules encoding E25a protein, and antibodies which bind E25a protein. E25a protein and its related molecules can be useful as diagnostic markers of cancer, including hormone refractory prostate cancer, and as specific therapeutic targets in this disease. The invention also provides methods for diagnosing cancer, including hormone refractory prostate cancer.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: July 25, 2000
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte, Charles L. Sawyers
  • Method and composition for detection of human chronic myelogenous leukemia
    Patent number: 4599305
    Abstract: A method for detecting chronic myelogenous leukemia in a human comprising the step of testing a biological sample from a patient to determine the presence of a marker protein (P210) which is characterized as a c-abl protein having tyrosine kinase activity and a molecular weight of approximately 210,000. Antisera which are specific for the P210 protein are disclosed which can be used to precipitate the P210 protein to allow identification by gel electrophoresis or other technique.
    Type: Grant
    Filed: July 16, 1984
    Date of Patent: July 8, 1986
    Assignee: The Regents of the University of California
    Inventors: Owen N. Witte, Susan Watanabe, James Konopka